Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
Omeros (OMER) Stock Price & Analysis
622 Followers
OMER Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.92 - $7.80
Previous Close$3.45
Volume374.90K
Average Volume (3M)394.23K
Market Cap
$199.91M
Enterprise Value$241.21M
Total Cash (Recent Filing)$171.85M
Total Debt (Recent Filing)$213.16M
Price to Earnings (P/E)-1.7
Beta2.14
Next Earnings
Aug 07, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding57,944,159
10 Day Avg. Volume352,642
30 Day Avg. Volume394,230
Standard Deviation0.26
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-7.68
Price to Sales (P/S)133.27
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue160.81
Enterprise Value/Gross Profit160.81
Enterprise Value/Ebitda-2.45
Forecast
1Y Price Target
$43.00Price Target Upside1146.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Omeros News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentOMER is progressing with innovative treatments, including OMS906, which is gaining interest in the medical community as data will be presented at a significant industry conference.
Financial HealthOMER has a robust financial position, underscored by a substantial cash reserve bolstered by non-dilutive revenue streams, ensuring operations are funded for multiple years ahead.
Regulatory MilestonesOMER is actively engaging with the FDA to advance its pipeline, including addressing regulatory feedback for narsoplimab and confirming the path forward for OMS906's clinical development.
Bears Say
Company OutlookSkeptical whether OMER can address the issues highlighted in the 2021 CRL.
Drug Approval ProcessSkeptical on whether a path to FDA approval for narsoplimab in HSCT-TMA exists after the agency requested additional info.
Regulatory ApprovalThe resubmission of the narsoplimab for HSCT-TMA remains in limbo with no clear date of resolution.
---
Ownership Overview
6.21% Insiders
8.99% Mutual Funds
19.97% Other Institutional Investors
64.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $0.92 and its highest was $7.80 in the past 12 months.
What is Omeros Corp’s market cap?
Currently, no data Available
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Aug 07, 2024 which is in 81 days.
How were Omeros Corp’s earnings last quarter?
Currently, no data Available
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -$0.7.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 57,944,160 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corp?
Among the largest hedge funds holding Omeros Corp’s share is Sheaff Brock Investment Advisors LLC. It holds Omeros Corp’s shares valued at 197K.
---
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (1146.38% Upside)
$43.00 (1146.38% Upside)
Blogger Sentiment
Bullish
OMER Sentiment 85%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.89%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
---
OMER Earnings Call
Q1 2024
0:00 / 0:00
---
OMER Stock 12 Month Forecast
Average Price Target
$43.00
▲(1146.38% Upside)
Technical Analysis
Adverum Biotechnologies
―
Aldeyra Therapeutics
―
Corbus Pharmaceuticals
―
Heron Therapeutics
―
Best Analysts Covering OMER
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+53.89%
reiterated a buy rating last month
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +53.89% per trade.
---